Aclarion (ACON)
Cloud-based MRI spectroscopy reports for identifying pain-associated lumbar discs.
Something off on this page? Send us feedback.
Adds magnetic resonance spectroscopy to lumbar MRI and sells cloud-processed Nociscan reports that classify discs by pain-associated chemistry. Revenue is earned per completed report, with delivery reliant on compatible scanners, imaging centers, reimbursement and clinical adoption.
Adds magnetic resonance spectroscopy to a conventional lumbar MRI workflow, then cloud-processes the scan data into Nociscan reports intended to help clinicians distinguish discs whose chemistry is consistent with pain from those whose chemistry is not. The platform comprises Nocicalc-LS for spectral processing and biomarkers, Nocigram-LS for physician-facing classifications, and the web-hosted Nociweb interface.
Sells completed reports rather than equipment, working through enabled imaging centers while clinicians refer patients being evaluated for surgery. Most reported revenue came from the United Kingdom, where private insurers reimburse the service; U.S. use remains mostly direct-pay or provider-paid.
Depends on compatible Siemens and Philips MRI configurations, external imaging and commercial partners, licensed University of California biomarkers, reimbursement progress, and clinical evidence. Nocigram is marketed as clinical-decision-support software under the company's regulatory self-classification.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $16.3M · Total debt $0 · Total assets $18.0M · Shareholders' equity $17.0M
- Revenue
- $25.2K
- Operating income
- −$2.9M
- Net income
- −$2.7M
No dividends on record.
| Institutions10 holders · as of Mar 31, 2026 | 3.91% | 112.6K shares | |
| Insiders9 holders · as of Aug 19, 2026 | 16.41% | 472.9K shares | |
| Strategic holders1 holder · as of Mar 25, 2026 | 8.47% | 244.0K shares | |
| Otherremainder | 71.21% | 2.05M shares |
2.88M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.88M in the company's Sep 3, 2026 report, 533.3K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
SEG Opportunity Fund, LLCStrategic | 8.47% | 244,043 | 13Gfiled Mar 25, 2026 ↗ |
Brent NessInsiderdirector, officer: Chief Executive Officer | 3.87% | 111,534 | Form 4filed Aug 17, 2026 ↗ |
Jeffrey John ThramannInsiderdirector, officer: Executive Chairman | 3.47% | 100,000 | Form 4filed Jun 12, 2026 ↗ |
Ryan BondInsiderdirector | 2.64% | 76,122 | Form 4filed Aug 17, 2026 ↗ |
Gregory A. GouldInsiderofficer: CFO | 2.08% | 60,000 | Form 4filed Aug 18, 2026 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Amanda M. Williams | director | +5,857 | $2.73 |
| Aug 14, 2026 | Gregory A. Gould | officer: CFO | +10,000 | $2.45 |
| Aug 13, 2026 | Brent Ness | director, officer: Chief Executive Officer | +5,234 | $2.31 |
| Aug 13, 2026 | David K. Neal | director | +7,500 | $2.40 |
| Aug 13, 2026 | William Wesemann | director | +2,150 | $2.34 |
- Philips (ADR)
Ingenia MRI is an incumbent platform in compatible Nociscan sites.
- GE HealthCare
SIGNA MRI offers an established anatomical imaging alternative for spine care.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aclarion | $2.35 | +0.64% | $1.2M | — | — | 14.7 | +30.5% |
| Philips (ADR) | $26.22 | −0.62% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| GE HealthCare | $70.63 | +0.13% | $31.87B | 20.5 | 13.6 | 1.6 | +5.8% |
| Median | 20.0 | 13.5 | 1.4 | +1.4% |